The MEBCDX AAV9 test kit was therefore developed as a CDx to be used as an aid in selecting anti-AAV9 antibody negative SMA patients for treatment with Zolgensma.
CrownBio is a leading contract research organization (CRO) in both the drug discovery and biomarker discovery arenas with a range of innovative product portfolios available across sites in Asia, th...
Agreements with CoMotion at the University of Washington and Dana-Farber Cancer Institute add new prostate cancer and lymphoma models to the world’s largest PDX collection
MBL has begun manufacturing the RUO kit, called FLUOROSEARCH Novel Coronavirus (SARS-CoV-2) Detection Kit, at a capacity of several tens of thousands of tests per month and will begin accepting ord...
ABSCI CLOSES $15.4 M IN SERIES D FUNDING TO ACCELERATE GROWTH AND SCALE DISRUPTIVE PROTEIN PRINTINGTM TECHNOLOGY, ANNOUNCES EXCLUSIVE CO-MARKETING PARTNERSHIP WITH KBI BIOPHARMA
The joint effort will target the development of a resin with high selectivity, high dynamic binding capacity and good chemical, especially caustic, resistance.
Selexis & Teneobio have signed CLAs for the development of Teneobio’s UniAbs™, a new class of multi-specific biologics, for the treatment of multiple myeloma, lymphoma and prostate cancer
The development will be based on PeptiDream’s proprietary drug discovery platform, PDPS (Peptide Discovery Platform System), and JSR’s extensive knowledge of affinity separation technology.
11 of 23
Receive JSR Life Sciences news on your RSS reader.
